

COMPLETE LISTING OF CLAIMS

1. (Previously Presented) An isolated antibody that is raised against and specifically binds one or more peptide selected from the group consisting of: Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
2. (Previously Presented) The isolated antibody of Claim 1, wherein said antibody is a monoclonal antibody.
3. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1).
4. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1).
5. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4).
6. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4).
7. (Previously Presented) The antibody of Claim 1, wherein said antibody specifically binds the peptide Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
8. (Previously Presented) The antibody of Claim 2, wherein said antibody specifically binds the peptide Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
9. (Original) The antibody of Claim 1, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

10. (Original) The antibody of Claim 2, wherein said antibody is cross-reactive with each of peptides Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1), Phe-Xaa-Gly-Leu-Met-NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4), and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).

11. (Canceled)

12. (Canceled)

13. (Canceled)

14. (Canceled)

15. (Canceled)

16. (Canceled)

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

23. (Canceled)

24. (Canceled)

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Previously Presented) A diagnostic reagent or kit comprising the antibody of Claim 1.

29. (Canceled)

30. A hybridoma that produces the antibody according to Claim 2.

31. (Canceled)
32. (New) An isolated antibody that specifically binds and is cross-reactive with peptide Phe-Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:1) and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2), or with peptides Phe-Xaa-Gly-Leu-Met- NH₂, where Xaa is variant Phe or Val (SEQ ID NO:4) and Phe-Gly-Leu-Met-NH₂ (SEQ ID NO:2).
33. (New) The isolated antibody of Claim 32, wherein said antibody is a monoclonal antibody.
34. (New) A hybridoma that produces the antibody of Claim 32.